NYSE · BMY
Healthcare · Drug Manufacturers - General
$59.59
Up+$0.11 (+0.18%)
Updated Oct 7, 2026, 10:39 PM
SID Score
6.4/10
Composite research score
Smart Money
47/100
Neutral
Price performance · BMY
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
BMY closed at $59.59 after 21 trading sessions, down 7.88% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $58.94 | $59.595 | $58.635 | $59.59 | 9.89M |
| Oct 5, 2026 | $59.89 | $60.15 | $58.33 | $58.81 | 19.24M |
| Oct 2, 2026 | $60.66 | $61.24 | $60.24 | $61.15 | 9.94M |
| Oct 1, 2026 | $62.20 | $62.61 | $61.25 | $61.46 | 10.77M |
| Sep 30, 2026 | $63.275 | $64.13 | $62.40 | $62.40 | 15.87M |
| Sep 29, 2026 | $63.58 | $63.89 | $61.95 | $62.86 | 15.84M |
| Sep 28, 2026 | $62.77 | $63.93 | $62.30 | $63.88 | 14.02M |
| Sep 25, 2026 | $61.75 | $62.91 | $61.395 | $62.86 | 10.67M |
| Sep 24, 2026 | $61.40 | $61.59 | $60.595 | $61.50 | 14.9M |
| Sep 23, 2026 | $62.31 | $62.65 | $61.075 | $61.15 | 15.84M |
| Sep 22, 2026 | $62.73 | $63.08 | $62.03 | $62.25 | 15.24M |
| Sep 21, 2026 | $63.09 | $63.395 | $62.62 | $62.62 | 6.84M |
| Sep 18, 2026 | $62.71 | $63.065 | $62.19 | $63.06 | 36.85M |
| Sep 17, 2026 | $64.08 | $64.35 | $62.52 | $62.84 | 12.21M |
| Sep 16, 2026 | $64.07 | $64.385 | $63.22 | $63.60 | 9.45M |
| Sep 15, 2026 | $63.94 | $64.13 | $63.15 | $63.73 | 10M |
| Sep 14, 2026 | $64.59 | $65.29 | $63.91 | $64.10 | 6.9M |
| Sep 11, 2026 | $64.15 | $64.20 | $63.27 | $63.64 | 7.06M |
| Sep 10, 2026 | $64.92 | $64.92 | $63.73 | $63.75 | 6.5M |
| Sep 9, 2026 | $64.57 | $65.05 | $64.2608 | $64.41 | 6.57M |
| Sep 8, 2026 | $65.66 | $65.8931 | $64.395 | $64.69 | 9.52M |
The latest Smart Investors Daily articles mentioning BMY.
Company
Market Activity
Research & News
BMY research
Company profile and research snapshot.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Leerink Partners | Market Perform | — |
| Sep 16, 2026 | Piper Sandler | Overweight | — |
| Sep 10, 2026 | HSBC | Hold | — |
| Aug 5, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
No generated briefing is available yet.
ChartMill · Oct 3, 2026
BMY passes ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but payout sustainability and falling EPS warrant income-investor caution.
Yahoo · Oct 3, 2026
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
Yahoo · Oct 1, 2026
PRINCETON, N.J., October 01, 2026--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Yahoo · Sep 30, 2026
PRINCETON, N.J., September 30, 2026--U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BMY.
